[SCHEDULE 13G/A] Theratechnologies Inc. Common SEC Filing
Schedule 13G/A (Amendment 3) filed by Morgan Stanley discloses that its ownership in Theratechnologies Inc. (THTX) has fallen below the 5 % reporting threshold. As of 30 Jun 2025, the bank beneficially owns 858,614 common shares (CUSIP 88338H704), equal to 1.9 % of the outstanding class.
- Sole voting power: 0 shares
- Shared voting power: 852,939 shares
- Sole dispositive power: 0 shares
- Shared dispositive power: 858,614 shares
The filer is classified as a parent holding company/control person (HC, CO). Morgan Stanley certifies the shares are held in the ordinary course of business and not with intent to influence control. The amendment serves to notify investors that Morgan Stanley is no longer a 5 %+ beneficial owner of THTX.
La Schedule 13G/A (Emendamento 3) presentata da Morgan Stanley rivela che la sua partecipazione in Theratechnologies Inc. (THTX) 猫 scesa al di sotto della soglia di segnalazione del 5%. Al 30 giugno 2025, la banca detiene beneficiariamente 858.614 azioni ordinarie (CUSIP 88338H704), pari al 1,9% della classe in circolazione.
- Potere di voto esclusivo: 0 azioni
- Potere di voto condiviso: 852.939 azioni
- Potere dispositive esclusivo: 0 azioni
- Potere dispositive condiviso: 858.614 azioni
Il dichiarante 猫 classificato come societ脿 madre/persona di controllo (HC, CO). Morgan Stanley certifica che le azioni sono detenute nell'ordinario corso degli affari e non con l'intento di influenzare il controllo. L'emendamento ha lo scopo di informare gli investitori che Morgan Stanley non 猫 pi霉 un azionista beneficiario superiore al 5% di THTX.
El Schedule 13G/A (Enmienda 3) presentado por Morgan Stanley revela que su participaci贸n en Theratechnologies Inc. (THTX) ha ca铆do por debajo del umbral de reporte del 5%. Al 30 de junio de 2025, el banco posee beneficiosamente 858,614 acciones ordinarias (CUSIP 88338H704), equivalentes al 1.9% de la clase en circulaci贸n.
- Poder de voto exclusivo: 0 acciones
- Poder de voto compartido: 852,939 acciones
- Poder dispositive exclusivo: 0 acciones
- Poder dispositive compartido: 858,614 acciones
El declarante est谩 clasificado como una compa帽铆a matriz/persona de control (HC, CO). Morgan Stanley certifica que las acciones se mantienen en el curso ordinario del negocio y no con la intenci贸n de influir en el control. La enmienda sirve para notificar a los inversores que Morgan Stanley ya no es un propietario beneficiario superior al 5% de THTX.
氇贝 鞀ろ儬毽皜 鞝滌稖頃� Schedule 13G/A (靾橃爼 3) 氍胳劀鞐� 霐半ゴ氅� Theratechnologies Inc.(THTX)鞐� 雽�頃� 氤挫湢 歆�攵勳澊 5% 氤搓碃 旮办靹� 鞎勲灅搿� 霒柎臁岇姷雼堧嫟. 2025雲� 6鞗� 30鞚� 旮办鞙茧, 鞚�頄夓潃 858,614 氤错喌欤�(CUSIP 88338H704)毳� 鞁れ鞝侅溂搿� 靻岇湢頃橁碃 鞛堨溂氅�, 鞚措姅 氚滍枆 欤检嫕鞚� 1.9%鞐� 頃措嫻頃╇媹雼�.
- 雼弲 鞚橁舶甓�: 0欤�
- 瓿惦彊 鞚橁舶甓�: 852,939欤�
- 雼弲 觳橂秳甓�: 0欤�
- 瓿惦彊 觳橂秳甓�: 858,614欤�
鞁犼碃鞛愲姅 氇殞靷�/韱奠牅鞚�(HC, CO)鞙茧 攵勲霅╇媹雼�. 氇贝 鞀ろ儬毽姅 頃措嫻 欤检嫕鞚� 靷梾鞚� 鞝曥儊鞝侅澑 瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 韱奠牅甓岇棎 鞓來枼鞚� 氙胳範 鞚橂弰臧� 鞐嗢潓鞚� 鞚胳頃╇媹雼�. 鞚措矆 靾橃爼鞚� 氇贝 鞀ろ儬毽皜 雿� 鞚挫儊 THTX鞚� 5% 鞚挫儊 鞁れ 氤挫湢鞛愱皜 鞎勲嫎鞚� 韴瀽鞛愳棎瓴� 鞎岆Μ旮� 鞙勴暅 瓴冹瀰雼堧嫟.
Le Schedule 13G/A (Amendement 3) d茅pos茅 par Morgan Stanley r茅v猫le que sa participation dans Theratechnologies Inc. (THTX) est pass茅e en dessous du seuil de d茅claration de 5 %. Au 30 juin 2025, la banque d茅tient b茅n茅ficiairement 858 614 actions ordinaires (CUSIP 88338H704), repr茅sentant 1,9 % de la classe en circulation.
- Pouvoir de vote exclusif : 0 actions
- Pouvoir de vote partag茅 : 852 939 actions
- Pouvoir dispositif exclusif : 0 actions
- Pouvoir dispositif partag茅 : 858 614 actions
Le d茅clarant est class茅 comme soci茅t茅 m猫re/personne de contr么le (HC, CO). Morgan Stanley certifie que les actions sont d茅tenues dans le cours normal des affaires et sans intention d鈥檌nfluencer le contr么le. L鈥檃mendement a pour but d鈥檌nformer les investisseurs que Morgan Stanley n鈥檈st plus un d茅tenteur b茅n茅ficiaire de plus de 5 % de THTX.
Der von Morgan Stanley eingereichte Schedule 13G/A (脛nderung 3) offenbart, dass deren Beteiligung an Theratechnologies Inc. (THTX) unter die Meldegrenze von 5 % gefallen ist. Zum 30. Juni 2025 besitzt die Bank wirtschaftlich 858.614 Stammaktien (CUSIP 88338H704), was 1,9 % der ausstehenden Aktienklasse entspricht.
- Alleiniges Stimmrecht: 0 Aktien
- Gemeinsames Stimmrecht: 852.939 Aktien
- Alleiniges Verf眉gungsrecht: 0 Aktien
- Gemeinsames Verf眉gungsrecht: 858.614 Aktien
Der Melder ist als Muttergesellschaft/Kontrollperson (HC, CO) klassifiziert. Morgan Stanley best盲tigt, dass die Aktien im gew枚hnlichen Gesch盲ftsverlauf gehalten werden und nicht mit der Absicht, Kontrolle auszu眉ben. Die 脛nderung dient dazu, Investoren dar眉ber zu informieren, dass Morgan Stanley nicht l盲nger ein wirtschaftlicher Eigent眉mer von mehr als 5 % an THTX ist.
- None.
- Morgan Stanley reduced its ownership in Theratechnologies to 1.9 %, down from a prior level above 5 %, potentially signalling diminished institutional support.
Insights
TL;DR: Morgan Stanley cut its THTX stake to 1.9 %; modestly negative signal, but limited fundamental impact.
The crossing of the 5 % threshold removes Morgan Stanley from the list of significant holders, suggesting a reduction in conviction or routine re-balancing. Because the bank still retains ~859 k shares, it has not fully exited. The filing carries governance significance鈥攍arge-block sales could add liquidity pressure鈥攜et it delivers no operational or financial data on Theratechnologies itself. For most investors, the news is a sentiment indicator rather than a fundamental catalyst; price impact will depend on whether additional institutional selling follows.
TL;DR: Loss of 5 % holder status changes disclosure obligations; governance impact is minor.
By dropping below 5 %, Morgan Stanley transitions from Schedule 13D/13G active monitoring to standard reporting, reducing future transparency on its position. This may slightly diminish shareholder oversight but does not alter board composition or control dynamics. The certification confirms passive intent, limiting takeover-related interpretations. Overall, the event is impactful for ownership structure tracking yet neutral for corporate governance stability.
La Schedule 13G/A (Emendamento 3) presentata da Morgan Stanley rivela che la sua partecipazione in Theratechnologies Inc. (THTX) 猫 scesa al di sotto della soglia di segnalazione del 5%. Al 30 giugno 2025, la banca detiene beneficiariamente 858.614 azioni ordinarie (CUSIP 88338H704), pari al 1,9% della classe in circolazione.
- Potere di voto esclusivo: 0 azioni
- Potere di voto condiviso: 852.939 azioni
- Potere dispositive esclusivo: 0 azioni
- Potere dispositive condiviso: 858.614 azioni
Il dichiarante 猫 classificato come societ脿 madre/persona di controllo (HC, CO). Morgan Stanley certifica che le azioni sono detenute nell'ordinario corso degli affari e non con l'intento di influenzare il controllo. L'emendamento ha lo scopo di informare gli investitori che Morgan Stanley non 猫 pi霉 un azionista beneficiario superiore al 5% di THTX.
El Schedule 13G/A (Enmienda 3) presentado por Morgan Stanley revela que su participaci贸n en Theratechnologies Inc. (THTX) ha ca铆do por debajo del umbral de reporte del 5%. Al 30 de junio de 2025, el banco posee beneficiosamente 858,614 acciones ordinarias (CUSIP 88338H704), equivalentes al 1.9% de la clase en circulaci贸n.
- Poder de voto exclusivo: 0 acciones
- Poder de voto compartido: 852,939 acciones
- Poder dispositive exclusivo: 0 acciones
- Poder dispositive compartido: 858,614 acciones
El declarante est谩 clasificado como una compa帽铆a matriz/persona de control (HC, CO). Morgan Stanley certifica que las acciones se mantienen en el curso ordinario del negocio y no con la intenci贸n de influir en el control. La enmienda sirve para notificar a los inversores que Morgan Stanley ya no es un propietario beneficiario superior al 5% de THTX.
氇贝 鞀ろ儬毽皜 鞝滌稖頃� Schedule 13G/A (靾橃爼 3) 氍胳劀鞐� 霐半ゴ氅� Theratechnologies Inc.(THTX)鞐� 雽�頃� 氤挫湢 歆�攵勳澊 5% 氤搓碃 旮办靹� 鞎勲灅搿� 霒柎臁岇姷雼堧嫟. 2025雲� 6鞗� 30鞚� 旮办鞙茧, 鞚�頄夓潃 858,614 氤错喌欤�(CUSIP 88338H704)毳� 鞁れ鞝侅溂搿� 靻岇湢頃橁碃 鞛堨溂氅�, 鞚措姅 氚滍枆 欤检嫕鞚� 1.9%鞐� 頃措嫻頃╇媹雼�.
- 雼弲 鞚橁舶甓�: 0欤�
- 瓿惦彊 鞚橁舶甓�: 852,939欤�
- 雼弲 觳橂秳甓�: 0欤�
- 瓿惦彊 觳橂秳甓�: 858,614欤�
鞁犼碃鞛愲姅 氇殞靷�/韱奠牅鞚�(HC, CO)鞙茧 攵勲霅╇媹雼�. 氇贝 鞀ろ儬毽姅 頃措嫻 欤检嫕鞚� 靷梾鞚� 鞝曥儊鞝侅澑 瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 韱奠牅甓岇棎 鞓來枼鞚� 氙胳範 鞚橂弰臧� 鞐嗢潓鞚� 鞚胳頃╇媹雼�. 鞚措矆 靾橃爼鞚� 氇贝 鞀ろ儬毽皜 雿� 鞚挫儊 THTX鞚� 5% 鞚挫儊 鞁れ 氤挫湢鞛愱皜 鞎勲嫎鞚� 韴瀽鞛愳棎瓴� 鞎岆Μ旮� 鞙勴暅 瓴冹瀰雼堧嫟.
Le Schedule 13G/A (Amendement 3) d茅pos茅 par Morgan Stanley r茅v猫le que sa participation dans Theratechnologies Inc. (THTX) est pass茅e en dessous du seuil de d茅claration de 5 %. Au 30 juin 2025, la banque d茅tient b茅n茅ficiairement 858 614 actions ordinaires (CUSIP 88338H704), repr茅sentant 1,9 % de la classe en circulation.
- Pouvoir de vote exclusif : 0 actions
- Pouvoir de vote partag茅 : 852 939 actions
- Pouvoir dispositif exclusif : 0 actions
- Pouvoir dispositif partag茅 : 858 614 actions
Le d茅clarant est class茅 comme soci茅t茅 m猫re/personne de contr么le (HC, CO). Morgan Stanley certifie que les actions sont d茅tenues dans le cours normal des affaires et sans intention d鈥檌nfluencer le contr么le. L鈥檃mendement a pour but d鈥檌nformer les investisseurs que Morgan Stanley n鈥檈st plus un d茅tenteur b茅n茅ficiaire de plus de 5 % de THTX.
Der von Morgan Stanley eingereichte Schedule 13G/A (脛nderung 3) offenbart, dass deren Beteiligung an Theratechnologies Inc. (THTX) unter die Meldegrenze von 5 % gefallen ist. Zum 30. Juni 2025 besitzt die Bank wirtschaftlich 858.614 Stammaktien (CUSIP 88338H704), was 1,9 % der ausstehenden Aktienklasse entspricht.
- Alleiniges Stimmrecht: 0 Aktien
- Gemeinsames Stimmrecht: 852.939 Aktien
- Alleiniges Verf眉gungsrecht: 0 Aktien
- Gemeinsames Verf眉gungsrecht: 858.614 Aktien
Der Melder ist als Muttergesellschaft/Kontrollperson (HC, CO) klassifiziert. Morgan Stanley best盲tigt, dass die Aktien im gew枚hnlichen Gesch盲ftsverlauf gehalten werden und nicht mit der Absicht, Kontrolle auszu眉ben. Die 脛nderung dient dazu, Investoren dar眉ber zu informieren, dass Morgan Stanley nicht l盲nger ein wirtschaftlicher Eigent眉mer von mehr als 5 % an THTX ist.
FAQ
Why did Morgan Stanley file an amended Schedule 13G/A for THTX?
How many Theratechnologies shares does Morgan Stanley currently own?
What percentage of THTX鈥檚 outstanding shares does this represent?
Does Morgan Stanley retain any voting power over its THTX stake?
Is Morgan Stanley attempting to influence control of Theratechnologies?
